Company Clarification on Price Movement
Summary of Company's Response
Beta Drugs Ltd submitted a formal response to the National Stock Exchange of India Limited regarding significant movement in the company's security price. The communication dated June 15, 2026, references the exchange's letter Ref. No. NSE/CM/Surveillance/17088 dated June 12, 2026.
Nature of Exchange Query
The National Stock Exchange raised concerns about significant movement in the price of the company's security, prompting a regulatory clarification request under surveillance procedures.
Company's Clarification on Trading Volume and Price Movement
The company explicitly confirmed that:
- There is no undisclosed price sensitive information
- There are no material events or announcements (including impending announcements) that could affect price/volume behavior
- The share price movement is purely market driven
- The company has no control over the market-driven price movement
Regulatory Compliance Reference
The company specifically referenced compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company reaffirmed its commitment to promptly inform stock exchanges of any material information as and when it arises.